R&D productivity continues to be the industry's grand challenge. We analyzed the R&D
input, output, and outcome of 16 leading research-based pharmaceutical companies over …

Highlights•Rising R&D expenditures reflect ongoing incremental efficiency decline.•Recent
stabilization in R&D efficiency may not indicate structural reversal.•Sustained turnaround in …

This study investigates the impact of firm-specific uncertainty on innovation performance and
how alliances moderate this relationship in the pharmaceutical industry. To reflect drug …

Within the context of the 'go global'strategy, for enabling enterprises to effectively form open
innovation strategies to enhance overseas business income and assume environmental …

Pharmaceutical managers have been encouraged to look to acquisitions and alliances for
innovation. However, the literature warns that the capacity of a company to 'absorb'new …

Collaboration among various organizations is important for the sustainable creation of new
innovative drugs. Previously, drug discovery was dominated by large pharmaceutical …

Background Intellectual property (IP) is a substantial competitive advantage in the health
care industry. However, the COVID-19 pandemic highlighted the need for open innovation …

Target 2035, an international federation of biomedical scientists from the public and private
sectors, is leveraging 'open'principles to develop a pharmacological tool for every human …

As the world increasingly prioritises environmental sustainability, small and medium-sized
enterprises (SMEs) must find innovative ways to develop green products. In the current …

Highlights•Gene therapy is becoming established in the treatment of rare diseases.•The
ease of starting clinical development has attracted startups, including those from academia.• …